Evidence map›Paper›PMID 39263622›Full record

ArticleBlood cell therapy2024

Long-term remissions with Gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3/NPM1 mutated acute myeloid leukemia.

E Tamellini, M Sorio, A Andreini, C Tecchio, G Nadali, A Bernardelli, I Ferrarini, L Crosera, A Vatteroni, C Simio and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cell therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Posttransplant cells for the win? DLI and adoptive cell therapy to eradicate MRD.Hematology. American Society of Hematology. Education Program · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

E TamelliniDepartment of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.
M SorioHematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
A AndreiniHematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
C TecchioDepartment of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.
G NadaliHematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
A BernardelliHematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
I FerrariniDepartment of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.
L CroseraDepartment of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.
A VatteroniDepartment of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.
C SimioDepartment of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.
F BenedettiHematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
M KramperaDepartment of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.
I TanasiHematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) relapse in patients with acute myeloid leukemia (AML) has an almost invariably dismal prognosis. Recent studies have demonstrated that FLT3 inhibition enhances the graft-versus-leukemia effect in vitro and in vivo. Thus, FLT-3 inhibitors may be viable treatment options in this setting. Here, we report three patients with FLT3 and NPM1 mutated AML who relapsed early after allo-HSCT and were treated with gilteritinib (associated with donor lymphocyte Infusion in two patients) to achieve long-term remission without a second transplantation.

Indexed as

acute myeloid leukemiaFLT3-inhibitorspost-transplant relapse

Identifiers

PMID39263622
PMCPMC11384128

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.